Pharmacovigilance & Medical Information: An Integrated Approach
Webinar date & time: May 16th 15:00 CET
Join our webinar and learn how you can achieve this integration from our real-world experience.
Are you interested in learning about the benefits of integrating Pharmacovigilance and Medical Information? Then, join us for our upcoming webinar, where we’ll discuss the advantages of combining these two critical components of drug safety.
Don’t miss out on this opportunity to expand your knowledge and stay up-to-date with the latest trends in drug safety. Register now and take your Pharmacovigilance and Medical Information management to the next level!
This webinar explores the benefits of integrated Pharmacovigilance and Medical Information. We’ll discuss how you can achieve this integration by sharing our real-world experience. Shortly? We aim to help you successfully integrate these functions and realize their positive impact on your operations and patient outcomes.
Join us to learn how integrated Pharmacovigilance and medical information can benefit your organization and ultimately improve patient care.
Register here!
Olga Asimaki - CMD, PhD.
International QPPV / Head of Global Medical Information
Olga Asimaki is a certified Medical Affairs professional with extensive experience in all aspects of Pharmacovigilance and Medical Information. Olga is a post-doctoral Neuroscientist holding an MSc from King’s College London and a PhD in Pharmacology. Before joining Biomapas, Olga was Head of Pharmacovigilance and Medical Information at AbbVie, leading and developing pharmacovigilance/medical information teams and systems. During her career, she has worked with global teams to successfully launch, implement and maintain a global medical information system and its processes.
Setting up Medical Information In Europe?
Let’s talk how we can team up to conduct them effectively and ensure smooth processes.
Other content that might interest you:
What do you need to know while preparing RMP for EAEU and CIS region?
Preparation of Risk Management Plan (RMP) for a specific medicinal product usually is the responsibility of the Qualified Person Responsible for Pharmacovigilance (QPPV) and its team. Thus, QPPVs and their team’s should be familiar with legislation requirements for RMP preparation in different regions. Within this article, we will concentrate on the Eurasian Economic Union (EAEU) and identify specific conditions of EAEU countries as well as to try to understand the expectations of Competent Authorities in this region.
MAH is the Key to the Pharmacovigilance: 10-year Lithuania Statistics
Even though the drug safety and reporting of the adverse effects is the responsibility of all Health Care Providers, pharmacists and patients, statistics show that the one in charge is Marketing Authorization Holder. During the National semi-annual conference „Pharmaceutical News“, State Medicines Control Agency presented the statistics of suspected ADRs reporting in Lithuania.
Biomapas appoints Head of Global Pharmacovigilance
March 2020 – Clinical, regulatory and pharmacovigilance solution provider to the global life science industry, Biomapas, appointed leading pharmacovigilance professional Martijn van de Leur as Head of Global Pharmacovigilance. With offices located in Lithuania, Switzerland, Sweden, Russia, Georgia, Ukraine and Poland, Biomapas provides services in 60+ countries across 4 continents. As a functional and full outsourcing solution provider, Biomapas continues to strengthen its international team and geographical coverage of its services globally.
